Outcome under regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Schedule ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved the unaudited standalone and consolidated financial results for Q2 and H1 FY26 ended September 30, 2025, with auditors issuing an unmodified (unqualified) Limited Review Report. On a consolidated basis, revenue from operations surged to Rs. 3,412.67 lakhs in Q2 FY26 (vs Rs. 10.92 lakhs in Q2 FY25) and Rs. 6,125.63 lakhs for H1 FY26, while net profit jumped to Rs. 635.34 lakhs in Q2 and Rs. 870.29 lakhs for H1 — the steep jump is largely due to consolidation of two newly acquired subsidiaries (Sai Machine Tools Pvt Ltd and Chemerix Life Sciences Pvt Ltd) from March 2025. Standalone numbers remain small (income essentially interest on loan to the subsidiary). The Board also approved hiking authorised share capital from Rs. 17 Cr to Rs. 18.10 Cr and a preferential issue of up to 15.5 lakh equity shares at Rs. 225 each (aggregating up to ~Rs. 34.88 Cr) to non-promoter investors, alongside calling an EGM to seek shareholder approval.
The preferential issue at Rs. 225 per share will raise up to ~Rs. 34.88 Cr of fresh capital but will dilute existing shareholders by roughly 8–9%. The apparent revenue and profit explosion is inorganic (driven by subsidiary consolidation from March 2025, not a like-for-like YoY comparison), so investors should look through the headline growth. Notably, consolidated operating cash flow remained sharply negative at Rs. (2,487.61) lakhs for H1 FY26, signalling the group is still cash-burn-heavy at the operating level despite the accounting profit.